title: Prevalence of patients with nonmetastatic prostate cancer on androgen deprivation therapy in the United States.
abstract: OBJECTIVE
  To provide the first comprehensive assessment of the number of men exposed to continuous androgen deprivation therapy (ADT) in the nonmetastatic setting in the United States.
  
  
  METHODS
  We assembled 2 point-prevalent cohorts on December 31, 2008: men aged 18-64 years enrolled in commercial health plans (MarketScan) and men aged ≥67 years enrolled in fee-for-service (FFS) Medicare (Medicare 5% sample). We identified men with nonmetastatic prostate cancer who were actively receiving continuous ADT (gonadotropin-releasing hormone agonists or bilateral orchiectomy) for at least 6 months on the point-prevalence date. The number of prevalent ADT users in the national commercially insured (45-64 years) and FFS Medicare (≥65 years) populations was extrapolated with person-level weights. Using age-specific prevalence estimates derived from the 2 data sources, the number of prevalent users in the entire U.S. male population aged ≥45 years was also estimated.
  
  
  RESULTS
  We estimate that 11,935 commercially insured men aged 45-64 years (95% confidence interval [CI], 11,310-12,561) and 115,468 FFS Medicare male beneficiaries aged ≥65 years (95% CI, 112,304-118,633) represented patients with nonmetastatic prostate cancer actively receiving continuous ADT for ≥6 months in the United States on December 31, 2008. Extrapolated to the total U.S. male population aged ≥45 years, this estimate was 188,916 (95% CI, 184,104-193,727).
  
  
  CONCLUSIONS
  Our findings suggest that a substantial number of men with nonmetastatic prostate cancer are managed with continuous ADT for ≥6 months during the course of their disease.
authors.affiliation: Center for Observational Research, Amgen Inc, Thousand Oaks, CA 91320, USA. karynsah@amgen.com
authors.forename: Karynsa
authors.initials: K
authors.lastname: Cetin
authors.forename: Shuling
authors.initials: S
authors.lastname: Li
authors.forename: Anne H
authors.initials: AH
authors.lastname: Blaes
authors.forename: Scott
authors.initials: S
authors.lastname: Stryker
authors.forename: Alexander
authors.initials: A
authors.lastname: Liede
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Arneson
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists* / Q000031:analogs & derivatives; D006264:Health Benefit Plans, Employee / Q000706:statistics & numerical data; D006801:Humans; D008297:Male; D006278:Medicare / Q000706:statistics & numerical data; D008875:Middle Aged; D009919:Orchiectomy / Q000706:statistics & numerical data*; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000628:therapy*; D014481:United States
chemical_list: D018931:Antineoplastic Agents, Hormonal; D007987:Gonadotropin-Releasing Hormone